Drugs / MEX-CD1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07236463 | Jun 2026 → Jun 2027 expected | acute kidney injury, infectious disease with sepsis | Nîmes University Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEX-CD1 | “The goal of this clinical trial is to learn if adding the iron-binding drug MEX-CD1 to dialysis fluid can help remove excess iron in adults with sepsis-associated acute kidney...” NCT07236463 ↗ |
| Known as | Metal EXtraction - Chitosan DOTAGA 1 | “This study will evaluate the performance and safety of adding a novel iron chelator named MEX-CD1 (Metal EXtraction - Chitosan DOTAGA 1) to dialysate during continuous...” PMID 41436269 ↗ Dec 2025 |
| Route | Other | “MEX-CD1 remains confined to the dialysate, separated from the patient's circulation by the dialysis membrane because of its molecular weight” NCT07236463 ↗ |